| This week's sponsor is Premier Research. | | | Discovering the Great Potential of Immuno-Oncology Drugs
Immuno-modulating agents have been around a long time, but for limited uses. New immuno-oncology pathways promise big advances against a wider range of cancers. Register now for our May 23 webinar. Premier Research. It's what we do. Best. |
Featured Story | Thursday, May 18, 2017 Shares in Incyte have leaped after the company reported positive results for its epacadostat—vying to be the first-in-class IDO1 inhibitor—alongside Merck's PD-1 blocker Keytruda. |
|
|
| This week's sponsor is Medpace. | | | |
Top Stories | Thursday, May 18, 2017 Shire's dominant position in the hereditary angioedema (HAE) market just firmed up with stellar data for its new candidate lanadelumab in the rare genetic disease class. |
|
|
| Thursday, May 18, 2017 President Donald Trump is considering switching up his attack on U.S. health research budgets by capping how much the National Institutes of Health can spend on indirect costs, The Atlantic reports. But while the plan moves the focus of cuts away from research and on to administration, it has still triggered strong reactions, including a claim it will “disembowel” a source of ingenuity. |
|
|
| Thursday, May 18, 2017 Roche has published early clinical data on its bispecific antibody in heavily pretreated patients with metastatic colorectal cancer. The readout hints that the T cell-activating antibody may improve outcomes in this hard-to-treat population when given as a monotherapy and in combination with anti-PD-L1 drug Tecentriq. |
|
|
| Thursday, May 18, 2017 The European biotech VC sector is set to get a €200 million ($223 million) injection of capital. Well-established VC shop Vesalius Biocapital is looking to build on the success of its Ogeda exit with a €150 million fund, while new entrant AurorA-TT is putting together a €50 million pot to bankroll technology transfers in Italy. |
|
|
| Wednesday, May 17, 2017 Robert Califf, the FDA commissioner under President Barack Obama, is in talks with Verily for a leadership position, CNBC reported Tuesday. |
|
|
| Thursday, May 18, 2017 Migraine drugs that target a protein called calcitonin gene-related peptide are among the hottest pipeline candidates in biotech. Now, London-based Heptares Therapeutics is entering the race, thanks to a $5 million payment from its research partner Teva, which has a goal of becoming a leader in the migraine market. |
|
|
| This week's sponsor is Cmed Research. | | | |
| | | Epizyme set its sights on the accelerated approval of tazemetostat despite a lukewarm reception to its data. Release Novartis invested in retinal cell protection biotech ONL Therapeutics. Statement Roche revealed it wants to add multiple sclerosis drugs to its pipeline through partnerships. Bloomberg article | |
|
Resources Sponsored By: Veeva Join this global webinar to learn a new approach for demonstrating medical affairs' impact with better metrics - beyond reach and frequency, enabling launch success and better engagement with strategic KOL insights, and increasing your organization's share of voice in the healthcare landscape. Presented By: Covance The ICH GCP E6 guideline has been revised to address the complexities associated with today’s clinical trials, and this concise white paper will help you understand the recent guideline changes. Learn how use of risk-based monitoring can help you comply with the guidelines and achieve efficiency in clinical trial design, implementation and reporting. Sponsored By: Veeva To thrive in a fiercely competitive market, life sciences companies need to set themselves apart by designing and executing the best trial and successfully deliver drugs to market first. Learn how a modern EDC can help. Sponsored By Reprints Desk Puzzled by Scientific Literature Access? Here is your guide for navigating knowledge management’s twists and turns! If yours is a small- or medium-sized biopharma business, we can help you putting the pieces together. Learn the secrets of top knowledge management experts who will show you how to search, discover, acquire and manage knowledge in new ways. Presented By: Covance The recent evolution of immunotherapies and their potential applications have greatly impacted patients’ options for effective oncology treatments. These advances have been powered in part by the use of biomarkers, companion diagnostics (CDx) and complementary diagnostics. Read the white paper. Sponsored By: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Sponsored By: DocuSign The patients who rely on your scientific leadership are expecting more. Sponsored By: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. Drug Development Boot Camp® 2017 November 15-16, 2017 | Boston, MA FierceBiotech Executive Breakfast- Tackling the Drug Price Problem: A Town Hall Debate June 21, 2017 | San Diego, CA FierceBiotech 2nd Drug Development Forum September 25-27, 2017 | Boston, MA MIXiii-BIOMED 2017 May 23-25, 2017 | Tel Aviv, Israel 8th Transparency and Aggregate Spend West May 23-24, 2017 | San Diego, CA Life Sciences Event of the Year! DIA 2017 Global Annual Meeting 2017 BIO International Convention: The Largest Global Biotech Partnering Event of the Year June 19-22 | San Diego, CA Rational Combinations 360° in Immuno-Oncology June 28-29, 2017 | New York, NY |
